DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Generic Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2017-2022" report to their offering.
The global generic drugs market was valued at around US$ 228.8 Billion in 2016, growing at a CAGR of around 9% during 2010-2016
The biggest catalyst for growth is an increasing global pharmaceutical spending trend towards generics. Continuously increasing healthcare expenditures have pushed governments and third-party payers to seek ways to control their healthcare expenditures. This is catalyzing an increasing demand for generics versus their branded counterparts. Another major driver of this industry is the continued patent cliff that is providing growing pipelines opportunities for generic firms. Similarly, a growth in the overall global population and aging demographics is also proving to be beneficial for the overall healthcare sector including generic drug manufacturers. Healthcare reforms in the US and other developed markets coupled with strong growth in emerging market are some other important drivers for the generic drugs market.
Key Topics Covered:
1 Preface
2 Research Methodology
3 Executive Summary
4 Introduction
5 Global Generic Drug Industry
6 Performance of Key Regions
7 Competitive Landscape
8 Generic Drug Manufacturing Process
9 Project Details, Requirements and Costs Involved
10 Loans and Financial Assistance
11 Project Economics
Companies Mentioned
- Freseunis
- Hospira
- Mylan
- Novartis - Sandoz
- Teva Pharmaceuticals
For more information about this report visit http://www.researchandmarkets.com/research/b6lxt6/generic_drugs
